Strong Signal for Investors: VR LIFE and H2 Global Group Validate the Value of European MedTech Innovation
AI-summarised brief · reviewed before publication
H2 Global Group, a European technology group, has strengthened its position by connecting capital with clinically validated healthcare innovations. Its investment in VR LIFE, a medical device company, has seen its value more than double to $1.38 million. VR LIFE is preparing for FDA certification to enter the US market, while H2 Global Group expands its intellectual property through its subsidiary, H2 Medical Technologies, with a patent-pending therapeutic platform combining molecular hydrogen and virtual reality.